Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Nanoform Finland

0,99 EUR

+6,24 %

3.631 følger denne virksomhed

NANOFH

First North Finland

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+6,24 %
-12,26 %
+19,18 %
+12,15 %
-28,82 %
-29,93 %
-70,29 %
-77,81 %
-80,44 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Læs mere
Markedsværdi
84,64 mio. EUR
Aktieomsætning
124,34 t EUR
Omsætning
2,78 mio.
EBIT %
-872,43 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
26.2
2026

Årsrapport '25

Alle
Analyse
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse13.11.2025, 06.00

Nanoform Capital Markets Day December 16th, 2025

Nanoform Finland
Selskabsmeddelelse12.11.2025, 06.10

Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set

Nanoform Finland
Selskabsmeddelelse11.11.2025, 06.00

Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License

Nanoform Finland

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse29.10.2025, 09.00

Invitation to Nanoform’s Q3 2025 Report Presentation

Nanoform Finland
Pressemeddelelse27.10.2025, 07.10

Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma

Nanoform Finland
Pressemeddelelse21.10.2025, 06.00

Results of Nanoform Collaborative Study to be Presented at the 2025 Partnership Opportunities in Drug Delivery (PODD) Summit

Nanoform Finland
Selskabsmeddelelse16.10.2025, 13.00

Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Nanoform Finland
Pressemeddelelse14.10.2025, 06.30

NANOFORM OUTLICENSES NANOENCORAFENIB AND SIGNS DEVELOPMENT AND COMMERCIALISATION AGREEMENT WITH A.FORALL AND IMGA

Nanoform Finland
Pressemeddelelse30.9.2025, 06.30

NANOFORM EXPANDS COMMERCIAL PRESENCE IN ASIA WITH A&LS PHARMA IN SOUTH KOREA

Nanoform Finland
Pressemeddelelse26.9.2025, 08.00

Nanoform Q3 2025 report day set for November 12th, 2025

Nanoform Finland
Pressemeddelelse11.9.2025, 05.10

Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit

Nanoform Finland
Selskabsmeddelelse21.8.2025, 05.10

Nanoform Q2 2025 report: Continued progress on many fronts, supportive first preliminary pivotal nanoenzalutamide study results

Nanoform Finland
Pressemeddelelse7.8.2025, 08.00

Invitation to Nanoform’s Q2 2025 Report Presentation

Nanoform Finland
Pressemeddelelse19.6.2025, 06.00

NANOFORM SECURES €5 MILLION R&D LOAN FROM BUSINESS FINLAND TO ADVANCE CLINICAL DEVELOPMENT OF NANOAPALUTAMIDE

Nanoform Finland
Selskabsmeddelelse17.6.2025, 17.32

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland
Selskabsmeddelelse17.6.2025, 17.32

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado

Nanoform Finland
Selskabsmeddelelse17.6.2025, 17.32

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma

Nanoform Finland
Selskabsmeddelelse17.6.2025, 17.30

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2025 on remuneration of the Board of Directors

Nanoform Finland
Pressemeddelelse12.6.2025, 05.10

Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide

Nanoform Finland
Pressemeddelelse3.6.2025, 05.10

DEVELOPMENT OF NANOFORMED TRASTUZUMAB FOR SUBCUTANEOUS INJECTION TO BE PRESENTED AT DDF SUMMIT IN BERLIN

Nanoform Finland
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.